Tybamate—A Perplexing Drug
Abstract
Tybamate was evaluated in a controlled, double-blind study conducted with 126 anxious neurotic patients seen in general practice. Tybamate produced significantly more improvement than placebo only at the final four-week evaluation. The largest tybamate-placebo differences were observed on measures of somatic manifestations of free anxiety, followed by measures of bound anxiety such as phobic-obsessive-compulsive symptoms. Severity of initial symptomatology was related to the patient's response to tybamate but not to placebo; those patients who were initially sickest improved significantly more than patients who were initially less sick.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
